Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    8,950 result(s) found. Displaying page 1 of 448.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005746-15 Sponsor Protocol Number: MN43964 Start Date*: 2022-08-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS) Relapsing Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) LT (Trial now transitioned) NO (Completed) SK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) HR (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001537-24 Sponsor Protocol Number: EMR100070-005 Start Date*: 2015-12-14
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer
    Medical condition: First Line Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) PT (Completed) LT (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) HU (Completed) PL (Completed) NL (Completed) FR (Completed) DK (Completed) BG (Completed) HR (Completed) CY (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003745-11 Sponsor Protocol Number: 1346-0014 Start Date*: 2024-03-02
    Sponsor Name:Boehringer Ingelheim
    Full Title: An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005607-13 Sponsor Protocol Number: NN8640-4467 Start Date*: 2022-07-15
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ...
    Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    23.0 100000004859 10066333 Idiopathic short stature LLT
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000345-70 Sponsor Protocol Number: M12-914 Start Date*: 2014-07-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in Her-2 Negative Metastatic or Locally Advanced Unresectable B...
    Medical condition: HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated mutation (BRCA1 and BRCA2) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) PT (Completed) DE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) NO (Completed) HU (Prematurely Ended) IT (Prematurely Ended) NL (Completed) LV (Completed) ES (Prematurely Ended) FR (Prematurely Ended) LT (Completed) EE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000645-14 Sponsor Protocol Number: EFC16035 Start Date*: 2020-10-13
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
    Medical condition: Primary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BG (Trial now transitioned) EE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) LV (Completed) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000983-41 Sponsor Protocol Number: ID-076A301 Start Date*: 2021-11-03
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death a...
    Medical condition: Acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) SK (Trial now transitioned) DK (Trial now transitioned) EE (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) IE (Prematurely Ended) GR (Trial now transitioned) PT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001134-11 Sponsor Protocol Number: 1305-0023 Start Date*: 2022-11-22
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Medical condition: Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038738 - Respiratory, thoracic and mediastinal disorders 10084309 Progressive fibrosing interstitial lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) FI (Trial now transitioned) SI (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004886-29 Sponsor Protocol Number: MN39158 Start Date*: 2018-05-22
    Sponsor Name:Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) EE (Completed) IE (Completed) CZ (Completed) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) FI (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SI (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-001091-34 Sponsor Protocol Number: 1305-0014 Start Date*: 2022-12-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) ES (Ongoing) DE (Completed) NO (Completed) EE (Completed) FI (Completed) SI (Completed) PT (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) IT (Completed) GR (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003123-32 Sponsor Protocol Number: M16-006 Start Date*: 2017-09-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IE (Completed) BG (Completed) AT (Completed) LV (Completed) PL (Completed) BE (Completed) NL (Completed) EE (Completed) SE (Completed) ES (Completed) GR (Completed) NO (Completed) LT (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003241-26 Sponsor Protocol Number: EP0093 Start Date*: 2018-09-04
    Sponsor Name:UCB Biopharma SPRL
    Full Title: An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy
    Medical condition: Focal-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BG (Completed) FR (Completed) LT (Completed) BE (Completed) PT (Prematurely Ended) EE (Completed) NL (Completed) DK (Completed) AT (Completed) GR (Completed) FI (Completed) NO (Completed) SE (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-003190-17 Sponsor Protocol Number: M15-991 Start Date*: 2017-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Fail...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IE (Completed) BG (Completed) AT (Completed) LV (Completed) PL (Completed) NL (Completed) EE (Completed) LT (Completed) ES (Completed) GR (Completed) BE (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001240-35 Sponsor Protocol Number: M14-433 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DE (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) NL (Completed) PL (Completed) DK (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) HR (Completed) SI (Completed) FR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-000642-62 Sponsor Protocol Number: M14-675 Start Date*: 2019-06-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: M14-675, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulc...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) LV (Completed) PT (Completed) FI (Completed) DE (Completed) GR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) CZ (Completed) LT (Completed) IE (Completed) BE (Completed) HU (Completed) ES (Completed) SK (Completed) PL (Completed) FR (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001226-18 Sponsor Protocol Number: M14-431 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) DE (Completed) PL (Completed) CZ (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) SI (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-000996-98 Sponsor Protocol Number: CSL112_3001 Start Date*: 2018-09-05
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
    Medical condition: Acute Coronary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000641-31 Sponsor Protocol Number: M14-234 Start Date*: 2016-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) FI (Completed) HU (Completed) CZ (Completed) SE (Completed) PL (Completed) IE (Completed) PT (Completed) DE (Completed) LV (Completed) LT (Completed) AT (Completed) GR (Completed) BE (Completed) EE (Completed) NO (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 13:39:45 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA